CAXMOTABART
UNII CE2Q4UW3HW

Substance Identification & Data

This profile provides standardized clinical and technical data for Caxmotabart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CE2Q4UW3HW.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2930815-95-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CE2Q4UW3HW

CAS Registry Number

2930815-95-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CAXMOTABART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C213395

National Cancer Institute reference terminology for clinical and research data.

INN ID

13277

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Caxmotabart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CAXMOTABART

Common Names & Synonyms

CAXMOTABART [INN]

H-GAMMA1 HEAVY CHAIN HUMANIZED (1-450) (VH (HOMO SAPIENS IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT (8.8.13) (26-33.51-58.97-109)) (1-120) -HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)), (223-214')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HUMANIZED (1'-225') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214') -11-MER CONTAINING 7 G AND A CAAX MOTIF (222'-225') WITH A SITE SPECIFIC CYSTEINE (222') (215'-225')); DIMER (229-229'':232-232'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB HER2 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB HER2 .KAPPA.-CHAIN FUSION PROTEIN WITH PEPTIDE (SYNTHETIC CAAX BOX-CONTAINING 11-AMINO ACID FRAGMENT), DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (RECEPTOR TYROSINE PROTEIN KINASE ERBB-2, EPIDERMAL GROWTH FACTOR RECEPTOR 2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, WITH THE L-KAPPA LIGHT CHAINS BEING FUSED AT THEIR C-TERMINAL END TO A 11-MER SEQUENCE CONTAINING A CAAX MOTIF (ISOPRENYLATION RECOGNITION SEQUENCE) WITH A SITE SPECIFIC CYSTEINE;

External Clinical & Regulatory Resources

Previous UNIICE2MEZ74RT

Next UNIICE2ZM7K4X5